New Method to Measure Lung Antibodies from the Lower Airways Could Boost Development of Mucosal Vaccines - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Noninvasive Lower-Airway Antibody Measurement May Advance Mucosal Vaccine Development

  • By

  • Debbie Bunch

  • November 16, 2026

Share

Objective:

Assess whether Particles in Exhaled Air (PExA) can noninvasively measure antigen-specific antibodies in the lower airways.

Approach:
  • Sampling: PExA collected aerosolized respiratory tract lining fluid from distal airways after participants inhaled HEPA-filtered air.
  • Study group and analysis: The analysis included samples from 28 health care workers, 18 of whom had confirmed COVID-19, influenza, or RSV. Researchers measured antigen-specific IgA and IgG.
Key Findings:
  • PExA measurements of antigen-specific IgA and IgG showed low variability.
  • PExA and serum IgG were strongly correlated; the authors suggested systemic contribution may account for lower-airway IgG levels.
  • IgA correlations between PExA and serum were weaker, which the authors suggested might reflect local lung production.
  • PExA antibody levels correlated with those in nasal secretions, which had a higher IgA/IgG ratio.
Interpretation:

The authors concluded that PExA offers a practical way to study lower-airway mucosal immunity and evaluate vaccines intended to induce mucosal responses.

Limitations:
  • The study was a proof of concept and included samples from 28 health care workers.
  • The authors called for further research to assess broader applicability and potential use in clinical or interventional studies.
Conclusion:

The authors identified PExA as a potential tool for evaluating next-generation mucosal vaccines and called for further study.

Sources:

Original Source(s)

Related Content